Actylis and Novo Nordisk Pharmatech A/S have entered into an agreement for the distribution of pharmaceutical grade benzalkonium chloride to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland.
By combining Novo Nordisk Pharmatech’s manufacturing expertise of pharmaceutical grade quaternary ammonium compounds (Quats) with Actylis’ knowledge and infrastructure in critical raw material distribution, the companies aim to provide customers with the best end-to-end service.
Ian Jenning, SVP-President Europe at Actylis explains: ”This new agreement, built on our existing partnership in North America, represents a major opportunity for Actylis Europe to complete our pharmaceutical product portfolio while supporting the development of Novo Nordisk Pharmatech BKC for new applications.”
“We are thrilled to strengthen our collaboration with Actylis; this will extend our high standards to these fundamental European markets. We look forward to a successful partnership in the coming years,” says Samia Kappe, Chief Commercial Officer at Novo Nordisk Pharmatech A/S.
